These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25324206)

  • 1. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN; Rivest P; Sanderson JT
    Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
    Audet-Walsh É; Yee T; Tam IS; Giguère V
    Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
    Kim HJ; Park YI; Dong MS
    Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
    Segal CV; Koufaris C; Powell C; Gooderham NJ
    Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
    Rivest P; Renaud M; Sanderson JT
    Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative, antiandrogenic and cytotoxic effects of novel caffeic acid derivatives in LNCaP human androgen-dependent prostate cancer cells.
    Sanderson JT; Clabault H; Patton C; Lassalle-Claux G; Jean-François J; Paré AF; Hébert MJ; Surette ME; Touaibia M
    Bioorg Med Chem; 2013 Nov; 21(22):7182-93. PubMed ID: 24080105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
    Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
    Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
    Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
    Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogenic activity of Riboflavin 5'-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines.
    Choi YH; Kim J; Shin JY; Kang NG; Lee S
    Eur J Pharmacol; 2022 Feb; 917():174743. PubMed ID: 34998793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular distribution of vinclozolin and its metabolites differently affects 5α-dihydrotestosterone (DHT)-induced PSA secretion in LNCaP cells.
    Marcoccia D; Smeriglio A; Mantovani A; Trombetta D; Lorenzetti S
    Reprod Toxicol; 2022 Aug; 111():83-91. PubMed ID: 35595151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
    Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
    Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
    Warriar N; Pagé N; Koutsilieris M; Govindan MV
    Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.